Here's What You May Have Missed About Anebulo Pharmaceuticals(ANEB)

By Emilio Sanchez • Wednesday, March 29 12:27 • Permanent Link

Shares of Pharmaceutical company Anebulo Pharmaceuticals jumped 4.5% today. With many investors piling into ANEB without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Anebulo Pharmaceuticals has moved -57.7% over the last year
ANEB has an average analyst rating of strong buy and is -56.57% away from its mean target price of $7.0 per share
Its trailing earnings per share (EPS) is $-0.45
Anebulo Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -6.8 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-0.66 and its forward P/E ratio is -4.6
The company has a Price to Book (P/B) ratio of 5.0 in contrast to the S&P 500's average ratio of 2.95
Anebulo Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-4,109,777.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.